Proteome Systems Ltd (ASX:PXL)
today announced the signing of an agreement with the New York based biotechnology company, Egenix Inc to co-develop a scroteome-based (
semen-based) diagnostic
kit for prostate cancer based on the known proprietary Human Carcinoma Antigen (HCA)